Aurinia Acquires Kezar to Fortify its Autoimmune Disease Pipeline

ROCKVILLE, MD – March 30, 2026 – Aurinia Pharmaceuticals, the company behind the successful lupus nephritis drug LUPKYNIS®, announced today a definitive agreement to acquire Kezar Life Sciences. The deal, structured with an upfront cash payment and a future value component, signals a significant strategic move by Aurinia to deepen its pipeline and expand its footprint in the competitive autoimmune disease market.

Under the terms of the merger agreement, Aurinia will acquire all outstanding shares of Kezar for $6.955 in cash per share. In addition, Kezar stockholders will receive one non-transferable contingent value right (CVR) per share. This CVR offers potential future payouts tied to the success of Kezar’s lead asset, zetomipzomib, as well as proceeds from existing collaborations and excess cash on Kezar's books. The transaction, which has been unanimously approved by Kezar's board, is expected to close in the second quarter of 2026.

At the heart of the acquisition is zetomipzomib, a first-in-class small molecule designed to selectively inhibit the immunoproteasome. This novel mechanism offers a targeted approach to taming the immune system, and the drug has shown considerable promise in a field desperate for new options.

A Strategic Bet on a First-in-Class Asset

For Aurinia, the acquisition is a calculated play to build upon its success and diversify its portfolio. The company's sole commercial product, LUPKYNIS® (voclosporin), was a landmark approval as the first oral therapy for active lupus nephritis (LN). While successful, reliance on a single product carries inherent risks in the volatile biopharmaceutical industry. By acquiring Kezar, Aurinia gains a late-stage asset that aligns perfectly with its core focus on autoimmune conditions with high unmet medical needs.

"With its successful track record developing and commercializing treatments for autoimmune diseases, Aurinia is well positioned to continue the development of this novel therapeutic agent,” said Chris Kirk, Chief Executive Officer of Kezar, in the official announcement.

The deal allows Aurinia to leverage its existing clinical development and commercial infrastructure, which was built around the complex lupus market. Zetomipzomib is being studied for lupus nephritis and systemic lupus erythematosus (SLE), but its most compelling near-term opportunity may lie in a different condition: autoimmune hepatitis (AIH).

This strategic acquisition not only adds a promising new drug candidate but also mitigates future pipeline gaps, positioning Aurinia for sustained growth in the immunology space. The move follows a period of strategic alignment for Aurinia, including recent changes in leadership that appear to have paved the way for this transaction.

The Promise and Peril of Zetomipzomib

The story of zetomipzomib is one of both significant promise and notable setbacks, making it a classic high-risk, high-reward biotech asset. Its potential was showcased in the PORTOLA Phase 2a study in patients with autoimmune hepatitis, a rare and chronic disease where the body's immune system attacks the liver.

In the study, zetomipzomib demonstrated what the company called "clinically meaningful steroid-sparing biochemical remissions." A significant portion of patients treated with the drug were able to achieve remission while substantially reducing or completely withdrawing from corticosteroids, the long-term use of which is associated with severe side effects like diabetes and osteoporosis. In a disease with no FDA-approved therapies, these results generated considerable excitement.

However, the drug's journey has been turbulent. In 2024, Kezar terminated a Phase 2b trial of zetomipzomib in lupus nephritis following several patient deaths, casting a shadow over the program. Later, in late 2025, the company's plans for a pivotal AIH trial were delayed when the FDA requested additional data before proceeding. These challenges likely contributed to Kezar's decision to conduct a strategic review, which ultimately culminated in the sale to Aurinia.

Crucially, the acquisition announcement noted that Kezar recently had "positive interactions" with the FDA regarding an accelerated development path for zetomipzomib in AIH. This regulatory turnaround was likely a key catalyst for the deal, providing Aurinia with renewed confidence in the drug's path to market.

Navigating a Complex Competitive Field

The acquisition strategically positions Aurinia in two distinct competitive landscapes. For autoimmune hepatitis, zetomipzomib could enter a market with a profound unmet need. There are currently no specifically approved treatments for AIH, and the pipeline of potential competitors is relatively small. If Aurinia can successfully navigate the final stages of clinical development, zetomipzomib could become a foundational therapy and capture a significant market share.

In contrast, the lupus nephritis and systemic lupus erythematosus markets are becoming increasingly crowded. Here, zetomipzomib would face competition not only from established biologics like GSK's Benlysta and AstraZeneca's Saphnelo but also from Aurinia's own LUPKYNIS. The field is also bracing for a wave of next-generation therapies, including other B-cell modulators, interferon inhibitors, and even revolutionary CAR-T cell therapies. By pursuing AIH as a lead indication, Aurinia is placing its bet on a clearer, less contested path to commercialization while retaining the option to later pursue the larger but more competitive lupus market.

Deconstructing the Deal: Cash, Contingency, and Confidence

The financial structure of the acquisition reflects the nuanced valuation of a clinical-stage biotech. The upfront cash payment of $6.955 per share provided immediate and certain value to Kezar's shareholders, a premium over its recent trading price. Kezar's stock rose nearly 20% on the news, indicating strong investor approval.

The inclusion of the CVR is a modern M&A tool designed to bridge the gap between a seller's optimism and a buyer's caution. It allows Kezar's investors to retain a stake in the future success of zetomipzomib without forcing Aurinia to overpay for an asset that still carries clinical and regulatory risk. The CVR's value is tied directly to future milestones, such as positive trial data or regulatory approvals, effectively creating a shared-risk, shared-reward scenario.

This structure provides a floor for Kezar investors while preserving the potential for significant upside if Aurinia successfully develops the drug. The deal also received a crucial vote of confidence from Tang Capital Partners, LP, a major Kezar shareholder holding approximately 9.0% of its stock, which has formally agreed to tender its shares in support of the transaction. For Aurinia, the deal is a calculated investment, with the ultimate cost dependent on its own ability to unlock the full potential of Kezar's science. The path forward for zetomipzomib is now in Aurinia's hands, and its success will determine the final value of this strategic acquisition.